# Assessing the feasibility and acceptability of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to reduce PTSD symptoms in WTC responders

> **NIH ALLCDC U01** · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · 2022 · $349,983

## Abstract

ABSTRACT
Posttraumatic Stress Disorder (PTSD) remains the most prevalent mental health (MH) diagnosis for first
responders involved with responding to the 9/11 World Trade Center (WTC) terrorist attacks, with rates of
PTSD much higher than that of the general population. There are a number of evidence-based treatments
(EBT) for PTSD, with the strongest evidence base for trauma focused therapies, which typically require that
patients engage with the index trauma and the associated fears and cognitions. This can be particularly difficult
for PTSD patients for whom avoidance is a key symptom. Although these treatments are well supported, they
are less effective in military and veteran populations in particular. Additionally, high dropout rates are observed
across treatments for PTSD, with some studies yielding dropout rates of over 30%. Given the high rates of
PTSD and the lower uptake of effective PTSD treatment among responders, there is a clear need to provide
brief, easily accessible treatments to WTC responders to alleviate PTSD symptoms. There is a growing body
of literature to support the use of vagus nerve stimulation (VNS) to treat a number of different disorders with
promising animal model research regarding the use of VNS to address some of the features of PTSD,
specifically, due to the impact that VNS has on key areas of the brain that are associated with fear extinction
and hyperarousal in particular. The current study aims to determine whether the use of a novel, safe, non-
invasive form of VNS, transcutaneous auricular VNS (taVNS), would be acceptable and feasible for use with
WTC responders who have PTSD, and whether the methodology involved with a larger randomized controlled
trial (RCT) to test taVNS efficacy would be acceptable and feasible. As such, the current study involves
conducting a formative phase evaluation in the context of a focus group with WTC responders with elevated
PTSD symptoms, in order to tailor the taVNS intervention and the pilot study methodology so that it’s relevant
and acceptable for use. The taVNS intervention will then be piloted in a randomized, double-blind placebo
controlled parallel-design study with 30 WTC responders affiliated with the Northwell Queens WTC Health
Program who have PTSD. Outcomes include taVNS intervention and study methodology feasibility and
acceptability. In addition, differences between baseline and post-treatment MH measures will be used to
generate hypotheses for a future larger RCT aimed at evaluating taVNS efficacy in PTSD symptom reduction
among a larger sample of WTC responders with PTSD. We will also use results to generate hypotheses
regarding potential mechanisms of action including the various inflammatory, neural and cardiovascular
changes that correlate with treatment outcomes. This pilot feasibility study is a first step toward bringing the
latest advances in non-invasive, easy to use bioelectronic medicine technology to a population with high rates
of PTSD who exper...

## Key facts

- **NIH application ID:** 10459181
- **Project number:** 5U01OH012050-02
- **Recipient organization:** FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
- **Principal Investigator:** Rebecca Schwartz
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2022
- **Award amount:** $349,983
- **Award type:** 5
- **Project period:** 2021-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10459181

## Citation

> US National Institutes of Health, RePORTER application 10459181, Assessing the feasibility and acceptability of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to reduce PTSD symptoms in WTC responders (5U01OH012050-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10459181. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*